Idera Pharmaceuticals, Inc.

Symbol: IDRA

NASDAQ

0.425

USD

Market price today

  • -97.1145

    P/E Ratio

  • 7.8442

    PEG Ratio

  • 26.50M

    MRK Cap

  • 0.00%

    DIV Yield

Idera Pharmaceuticals, Inc. (IDRA) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

58.88%

Operating Profit Margin

680.24%

Net Profit Margin

665.27%

Return on Assets

-0.42%

Return on Equity

-1.90%

Return on Capital Employed

-0.55%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Vincent Milano
Full-time employees:13
City:Exton
Address:505 Eagleview Blvd Ste 212
IPO:1996-01-25
CIK:0000861838

Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.

General Outlook

When we look at how much money they make before expenses, they keep 58.878% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 680.245%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 665.265%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.415% return, is a testament to Idera Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Idera Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.897%. Furthermore, the proficiency of Idera Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.550% return on capital employed.

Stock Prices

Idera Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $0.3162, while its low point bottomed out at $0.306. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Idera Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing IDRA liquidity ratios reveals its financial health of the firm. The current ratio of 31.55% gauges short-term asset coverage for liabilities. The quick ratio (24.19%) assesses immediate liquidity, while the cash ratio (11.86%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio31.55%
Quick Ratio24.19%
Cash Ratio11.86%

Profitability Ratios

IDRA profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 67744.90% underscores its earnings before tax deductions. The effective tax rate stands at 1.80%, revealing its tax efficiency. The net income per EBT, 98.20%, and the EBT per EBIT, 99.59%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 68024.49%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin67744.90%
Effective Tax Rate1.80%
Net Income per EBT98.20%
EBT per EBIT99.59%
EBIT per Revenue68024.49%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.32, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding24
Operating Cycle-16410.10
Days of Payables Outstanding439
Cash Conversion Cycle-16849
Receivables Turnover-0.02
Payables Turnover0.83
Fixed Asset Turnover-0.10

Cash Flow Ratios

Lastly, the operating cash flow sales ratio, 470.53, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow Sales Ratio470.53
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-46.67
Short Term Coverage Ratio-103.39

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 0.63%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.02, we discern the balance between debt and equity financing. The long-term debt to capitalization, 1.19%, and total debt to capitalization, 2.14%, ratios shed light on its capital structure. An interest coverage of 243.30 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio0.63%
Debt Equity Ratio0.02
Long Term Debt to Capitalization1.19%
Total Debt to Capitalization2.14%
Interest Coverage243.30
Cash Flow to Debt Ratio-46.67
Company Equity Multiplier3.48

Per Share Data

Net income per share, -7.18, reflects the portion of profit attributed to each share. The book value per share, 3.63, represents the net asset value distributed per share, while the tangible book value per share, -13.44, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-7.18
Book Value Per Share3.63
Tangible Book Value Per Share-13.44
Shareholders Equity Per Share3.63
Interest Debt Per Share0.23

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -10,344,523.2, captures the company's total value, considering both debt and equity. Income quality, 1.05, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value-10,344,523.2
Income Quality1.05
Intangibles to Total Assets81.79%
Graham Number24.22
Return on Tangible Assets-126.91%
Graham Net Net-14.43
Working Capital-3,560,000
Tangible Asset Value-43,766,000
Net Current Asset Value-44,310,000
Average Receivables2,104,000
Average Payables2,882,500
ROIC-187.30%
ROE-1.98%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 140.40, and the price to book ratio, 140.40, reflect the market's valuation relative to the company's book value.

cards.indicatorcards.value
Price Book Value Ratio140.40
Price to Book Ratio140.40
Price Cash Flow Ratio-137.31
Price Earnings to Growth Ratio7.84
Enterprise Value Multiple-0.05
Price Fair Value140.40
Price to Operating Cash Flow Ratio-137.31
Price to Tangible Book Ratio0.10
Enterprise Value Over EBITDA0.37
EV to Operating Cash Flow0.42
Earnings Yield-2050.06%
Free Cash Flow Yield-2149.67%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Idera Pharmaceuticals, Inc. (IDRA) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -97.115 in 2024.

What is the ticker symbol of Idera Pharmaceuticals, Inc. stock?

The ticker symbol of Idera Pharmaceuticals, Inc. stock is IDRA.

What is company IPO date?

IPO date of Idera Pharmaceuticals, Inc. is 1996-01-25.

What is company current share price?

Current share price is 0.425 USD.

What is stock market cap today?

The market cap of stock today is 26501046.000.

What is PEG ratio in 2024?

The current 7.844 is 7.844 in 2024.

What is the number of employees in 2024?

In 2024 the company has 13.